title: Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer.
abstract: During the 1995 Multinational Association of Supportive Care in Cancer (MASCC) Congress, a consensus conference was planned by the Subcommittee for Antiemetics. To define the topics to be discussed, a questionnaire containing both clinical and methodological issues was sent to 118 experts in 31 countries. The questionnaire contained 33 items on clinical and 19 items on methodological issues, and each response was rated on a 4-level categorical scale. The clinical issues were evaluated for interest, that is clinical importance, and feasibility, that is availability of sufficient data to make them suitable topics for the consensus conference. About 60% of questionnaires were returned, with a small number of missing responses. The responses to the items of clinical interest showed that about two-thirds of the issues identified by the Subcommittee were found by the experts to be of at least high interest, but often the availability of data was found to be insufficient for their discussion. Prevention of acute emesis induced by cisplatin and by moderately emetogenic chemotherapy and the optimal intravenous dose and schedule of the 5-HT3 receptor antagonists were the items with the highest interest and feasibility. The issues in the methodological section were also mostly found to be of at least high interest. The distinction between acute and delayed emesis, the evaluation of the persistence of antiemetic efficacy in subsequent cycles of chemotherapy and the statistical analysis of delayed emesis were the methodological issues in which the highest interest was recorded. Data collected will be used to define the main topics to be discussed during the planned consensus conference.
authors.affiliation: Medical Oncology Division, Policlinico Hospital, Perugia, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Ballatori
authors.forename: F
authors.initials: F
authors.lastname: Roila
authors.forename: V
authors.initials: V
authors.lastname: De Angelis
authors.forename: G
authors.initials: G
authors.lastname: Ciccarese
authors.forename: M A
authors.initials: MA
authors.lastname: Palladino
authors.forename: M
authors.initials: M
authors.lastname: Tonato
authors.forename: A
authors.initials: A
authors.lastname: Del Favero
authors.forename: J
authors.initials: J
authors.lastname: Herrstedt
authors.forename: M
authors.initials: M
authors.lastname: Dicato
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: P
authors.initials: P
authors.lastname: Hesketh
authors.forename: M
authors.initials: M
authors.lastname: Kris
authors.forename: R J
authors.initials: RJ
authors.lastname: Gralla
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D006801:Humans; D009325:Nausea / Q000209:etiology / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D010166:Palliative Care; D011878:Radiotherapy / Q000009:adverse effects; D011795:Surveys and Questionnaires; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents